Exponential Genomics (Xenomics) is building next-generation life science companies focused on combating the world’s greatest challenges—feeding, fueling, and healing humanity. Built by a team of scientists trained at Harvard and MIT, our core technology is a novel gene-editing technique capable of performing over 400 years of CRISPR in 8 weeks. Our Xenoarray technology is well-positioned to revolutionize gene editing techniques by enabling gene knock-ins of up to 8,000 base pairs or 8 unique genes. We anticipate obtaining at least 3,000 unique cell lines from each experiment, which could radically streamline the process of integrating parallel workflows in bioengineering. Exponential’s current commercialization projects include streamlining the manufacturing of biopharmaceuticals, vaccines, human breastmilk, cell therapies, cultured meats & dairy, water desalination, carbon recycling, cannabinoids, psychedelics, food flavors, and perfume scents.